These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 11771654

  • 1. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [Abstract] [Full Text] [Related]

  • 2. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 3. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 4. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C.
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [Abstract] [Full Text] [Related]

  • 5. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL.
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [Abstract] [Full Text] [Related]

  • 6. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.
    Arch Intern Med; 2004 Oct; 157(22):2617-24. PubMed ID: 9531231
    [Abstract] [Full Text] [Related]

  • 7. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 8. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y, Wong M, Thiebaud D, Stock JL.
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [Abstract] [Full Text] [Related]

  • 9. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 10. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O.
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [Abstract] [Full Text] [Related]

  • 11. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [Abstract] [Full Text] [Related]

  • 13. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [Abstract] [Full Text] [Related]

  • 14. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 15. A comprehensive review of treatments for postmenopausal osteoporosis.
    Häuselmann HJ, Rizzoli R.
    Osteoporos Int; 2003 Jan 13; 14(1):2-12. PubMed ID: 12577179
    [Abstract] [Full Text] [Related]

  • 16. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec 13; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 17. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 13; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 18. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 13; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 19. Raloxifene: results from the MORE study.
    Agnusdei D, Iori N.
    J Musculoskelet Neuronal Interact; 2000 Dec 13; 1(2):127-32. PubMed ID: 15758505
    [Abstract] [Full Text] [Related]

  • 20. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Dec 13; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.